Amylyx Pharmaceuticals, Inc. - Common Stock — 四半期貸借対照表 (NASDAQ:AMLX) | MetaTrader

チャート全体を表示 Full chart

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.

ニュース

H.C. Wainwrightが治験への確信からAmylyx株の目標株価を34ドルに引き上げ

H.C. Wainwright raises Amylyx stock price target to $34 on trial confidence

Amylyx Pharmaceuticals、TD Cowenでアベキシチドなどの戦略的見解を提示

Amylyx株、試験の不透明感で3%超下落、決算予想上回るも

Amylyx shares fall over 3% on trial uncertainty despite earnings beat

Stifelが医薬品の潜在性を評価しAmylyx株を買い推奨で開始

Stifel initiates Amylyx stock with buy rating on drug potential

Amylyx、avexitide試験の終了が近づく中で決算発表へ

Amylyx set to report earnings as avexitide trial nears finish

H.C. ワインライト、アミリックス・ファーマシューティカルズの目標株価を20ドルから28ドルに引き上げ

Amylyx stock price target raised to $28 from $20 at H.C. Wainwright

Amylyx Pharmaceuticals: Back From The Dead (NASDAQ:AMLX)